Compare Global X Cybersecurity (BUG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cybersecurity vs ResMed Inc. — how do they compare? Global X Cybersecurity trades at $41.47, while ResMed Inc. trades at $198.58 (market cap $28.00B). The key difference: ResMed Inc. pays a 1.24% dividend while Global X Cybersecurity pays none, and Global X Cybersecurity is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| BUG | RMD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $41.99 | $293.73 |
52-Week Low | $23.30 | $182.82 |
Market Cap | — | $28.00B |
Enterprise Value | — | $27.18B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUG trades at $39.64, up 0.69% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces resistance near $40 and support at $39. Recent news highlights strong cybersecurity sector tailwinds, with global spending exceeding $300 billion in 2026, though the ETF faces competition from semiconductor-focused alternatives.
Outlook remains positive given cybersecurity's essential role in AI-driven cloud expansion, but valuation premiums and sector competition pose risks. The stock's performance hinges on continued enterprise budget growth and its ability to maintain relevance against disruptive AI technologies.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
